SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:umu-202681"
 

Sökning: onr:"swepub:oai:DiVA.org:umu-202681" > Local treatment of ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006029naa a2200673 4500
001oai:DiVA.org:umu-202681
003SwePub
008230112s2023 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:29b0e1c5-b64e-4d06-b230-b884030b2c6e
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-2026812 URI
0247 a https://doi.org/10.1016/j.euros.2022.11.0082 DOI
0247 a https://lup.lub.lu.se/record/29b0e1c5-b64e-4d06-b230-b884030b2c6e2 URI
040 a (SwePub)umud (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Marconi, Lorenzou University Hospital of Coimbra4 aut
2451 0a Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups
264 1b Elsevier,c 2023
338 a electronic2 rdacarrier
520 a BACKGROUND: Retrospective comparative studies suggest a survival benefit after complete local treatment of recurrence (LTR) in renal cell carcinoma (RCC), which may be largely due to an indication bias.OBJECTIVE: To determine the role of LTR in a homogeneous population characterised by limited and potentially resectable recurrence.DESIGN SETTING AND PARTICIPANTS: RECUR is a protocol-based multicentre European registry capturing patient and tumour characteristics, risk of recurrence (RoR), recurrence patterns, and survival of those curatively treated for nonmetastatic RCC from 2006 to 2011. Per-protocol resectable disease (RD) recurrence was defined as (1) solitary metastases, (2) oligometastases, or (3) renal fossa or renal recurrence after radical or partial nephrectomy, respectively.INTERVENTION: Local treatment of recurrence.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and cancer-specific survival was compared in the RD population that underwent LTR versus no LTR. We constructed a multivariate model to predict risk factors for overall mortality and analysed the effect of LTR across RoR groups.RESULTS AND LIMITATIONS: Of 3039 patients with localised RCC treated with curative intent, 505 presented with recurrence, including 176 with RD. Of these patients, 97 underwent LTR and 79 no LTR. Patients in the LTR group were younger (64.3 [40-80] vs 69.2 [45-87] yr; p = 0.001). The median OS was 70.3 mo (95% confidence interval [CI] 58-82.6) versus 27.4 mo (95% CI 23.6-31.15) in the LTR versus no-LTR group (p < 0.001). After a multivariate analysis, having LTR (hazard ratio [HR] 0.37 [95% CI 0.2-0.6]), having low- versus high-risk RoR (HR 0.42 [95% CI [0.20-0.83]), and not having extra-abdominal/thoracic metastasis (HR 1.96 [95% CI 1.02-3.77]) were prognostic factors of longer OS. The LTR effect on survival was consistent across risk groups. OS HR for high, intermediate, and low risks were 0.36 (0.2-0.64), 0.27 (0.11-0.65), and 0.26 (0.08-0.8), respectively. Limitations include retrospective design.CONCLUSIONS: This is the first study assessing the effectiveness of LTR in RCC in a comparable population with RD. This study supports the role of LTR across all RoR groups.PATIENT SUMMARY: We assessed the effectiveness of local treatment of resectable recurrent renal cell carcinoma after surgical treatment of the primary kidney tumour. Local treatment of recurrence was associated with longer survival across groups with a risk of recurrence.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Metastasectomy
653 a Metastatic
653 a Radiotherapy
653 a Renal cell cancer
653 a Stereotactic body radiotherapy
653 a Surgery
653 a Systemic therapy
653 a Metastasectomy
653 a Metastatic
653 a Radiotherapy
653 a Renal cell cancer
653 a Stereotactic body radiotherapy
653 a Surgery
653 a Systemic therapy
7001 a Kuusk, Teeleu Royal London Hospital4 aut
7001 a Capitanio, Umbertou San Raffaele Hospital4 aut
7001 a Beisland, Christianu Haukeland University Hospital,University of Bergen4 aut
7001 a Lam, Thomasu University of Aberdeen4 aut
7001 a Pello, Sergio Fernandezu University Hospital Cabueñes4 aut
7001 a Stewart, Grant Du Cambridge University Hospitals NHS Foundation Trust,University of Cambridge4 aut
7001 a Klatte, Tobiasu Charité - University Medicine Berlin4 aut
7001 a Volpe, Alessandrou University of Eastern Piedmont4 aut
7001 a Ljungberg, Börje,c Professor,d 1949-u Umeå University,Umeå universitet,Urologi och andrologi4 aut0 (Swepub:umu)bolj0001
7001 a Dabestani, Saeedu Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urologi,Urological cancer, Malmö,Lund University Research Groups,Urology4 aut0 (Swepub:lu)med-sdd
7001 a Bex, Axelu Antoni Van Leeuwenhoek Hospital,University College London4 aut
7102 a University Hospital of Coimbrab Royal London Hospital4 org
7730 t European Urology Open Scienced : Elsevierg 47, s. 65-72q 47<65-72x 2666-1691x 2666-1683
8564 u https://doi.org/10.1016/j.euros.2022.11.008y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:1726191/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u http://dx.doi.org/10.1016/j.euros.2022.11.008x freey FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-202681
8564 8u https://doi.org/10.1016/j.euros.2022.11.008
8564 8u https://lup.lub.lu.se/record/29b0e1c5-b64e-4d06-b230-b884030b2c6e

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy